Clinical trial NCT02418000: A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations
Official title: A Phase 1/2a Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations, Including Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: AML
MDS
CMML
Lead sponsor: Spirita Oncology, LLC
Sponsor class: INDUSTRY
First posted: 2015-04-16
Enrollment: 27
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This is a Phase 1/2a dose-escalation study of E6201, a dual mitogen-activated protein kinase/extracellular-signal regulated kinase 1 (MEK1) and FMS-like tyrosine kinase 3 (FLT3) inhibitor, in subjects with advanced hematologic malignancies with documented FLT3 and/or rat sarcoma (Ras) mutations. The Phase1 portion of the study will be a safety run-in (up to 30 subjects) to establish a recommended Phase 2 dose (RP2D). The Ph. 2a portion of the study will evaluate three specific patients groups: Cohort 1 will enroll patients with relapsed or refractory AML and confirmed FLT3 mutation (with or without a Ras mutation) without prior exposure to a FLT3 inhibitor; Cohort 2 will enroll patients with relapsed or refractory AML and confirmed FLT3 mutation (with or without a Ras mutation) with prior exposure to a FLT3 inhibitor; Cohort 3 will enroll patients with relapsed or refractory AML with a confirmed Ras mutation and no FLT3 mutation.

Detailed description: Phase 1 (Safety Run-In): Following Screening, a total of up to 30 subjects in up to 5 dose cohorts to establish the RP2D. The safety run-in phase will be a standard 3+3 cohort design.

Phase 2a (Expansion): Once the Phase 1 Safety Run-In portion of the study is complete and an RP2D is established, additional subjects will be enrolled into the Phase 2 Expansion portion in three cohorts. Cohort 1 will enroll up to 26 patients with relapsed or refractory AML and confirmed FLT3 mutation (with or without a Ras mutation) without prior exposure to a FLT3 inhibitor. Cohort 2 will enroll up to 26 patients with relapsed or refractory AML and confirmed FLT3 mutation (with or without a Ras mutation) with prior exposure to a FLT3 inhibitor. Cohort 3 will enroll up to 10 patients with relapsed or refractory AML with a confirmed Ras mutation and no FLT3 mutation. Cohort 1 and 2 of the Expansion Phase will incorporate a Simon 2-stage optimal design. Subjects with AML enrolled in the Phase 1 portion of the study at the RP2D will count towards the Phase 2a accrual for the appropriate cohort.

Subjects will receive E6201 weekly or bi-weekly on a 28-day schedule, with the schedule and dose level established in the Safety Run-In portion of the study. Disease assessments, including analysis of blood and bone marrow samples, will be performed at the end of Cycles 1 and 3 and every 2 cycles thereafter. Disease assessments may be made at other time points at the discretion of the Investigator.

Subjects who demonstrate clinical benefit (objective response or stable disease) will be allowed to continue therapy with E6201 until progression of disease, observation of unacceptable adverse events, intercurrent illness or changes in the patient's condition that prevents further study participation.

During the study, ECGs will be performed, blood will be collected for hematology, serum chemistry, pharmacokinetics and pharmacodynamics assessments, and bone marrow will be collected for the assessment of disease response and mutational status.

Eligibility criteria: Inclusion Criteria:

* Males and females ≥ 18 years of age
* Phase 1: Confirmed relapsed or refractory AML with a documented FLT3 and/or Ras mutation, or ≥ 60 years with newly diagnosed FLT3+ and/or Ras+ AML and not eligible for standard induction chemotherapy or FLT3+ and/or Ras+ higher-risk MDS/CMML (defined as ≥ 10% marrow blasts or ≥ 5% peripheral blood blasts or Revised International Prognostic Scoring System \[IPSS-R\] score ≥ 3.5) and relapsed or refractory to prior therapy
* Phase 2: Confirmed relapsed or refractory AML with a documented FLT3 and/or Ras mutation, or age ≥ 60 years with newly diagnosed FLT3+ and/or Ras+ AML and not eligible for standard induction chemotherapy
* At least 3 weeks beyond the last cancer treatment for the disease under study, major surgery and recovered from all acute toxicities (≤ Grade 1) by first dose of study drug (C1D1). Hydroxyurea used to control peripheral blast counts is permitted during the first 2 cycles.
* Adequate performance status Eastern Cooperative Oncology Group (ECOG) ≤ 2
* Adequate renal and hepatic function:

  * creatinine ≤ 1.5 mg/dL OR calculated creatinine clearance ≥ 45 mL/minute
  * total bilirubin ≤ 2 times the upper limit of normal (ULN) unless due to Gilbert's disease or thought to be due to underlying AML
  * ALT and AST ≤ 5 times ULN
* Negative serum pregnancy test within 14 days prior to the first dose of study therapy for women of child-bearing potential (WCBP). Sexually active WCBP and male subjects must agree to use adequate methods to avoid pregnancy throughout the study and for 28 days after completion of study treatment.
* Ability to provide written informed consent

Exclusion Criteria:

* History of clinically significant cardiac impairment, congestive heart failure (CHF) New York Heart Association (NYHA) Class III or IV, unstable angina, or myocardial infarction during the previous 6 months, or serious cardiac arrhythmia
* QT interval corrected for rate (QTc) ≥ 450 msec for males and ≥ 460 msec for females on the ECG obtained at Screening using Fridericia method for QTc calculation (average of 3 readings)
* Concomitant medication(s) that may cause QTc prolongation or induce Torsades de Pointes with the exception of anti-microbials used as standard of care to prevent or treat infections and other such drugs that are considered by the investigator to be essential for the care of the patient. However, if such medications are deemed to be necessary during the study, more extensive ECG monitoring will be added during the period of concomitant drug administration.
* Presence of active central nervous system (CNS) leukemia. Subjects adequately treated for CNS leukemia documented by 2 consecutive cerebrospinal fluid samples negative for leukemia cells are eligible. Subjects with no history of CNS leukemia will not be required to undergo cerebrospinal fluid sampling for eligibility.
* Known positive for human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBsAg), or hepatitis C virus HCV)
* Active, uncontrolled infection
* Known hypersensitivity to any study drug component
* History of another malignancy; Exception: Patients disease-free for 2 years or treated in situ carcinoma
* Any other medical intervention or other condition which, in the opinion of the Principal Investigator, could compromise adherence to study requirements or confound the interpretation of study results
* Pregnancy or lactation

Primary outcomes:
measure: Maximum Tolerated Dose (MTD) of E6201
timeFrame: Up to 6 weeks for each dose cohort
measure: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)
timeFrame: Up to 6 weeks for each dose cohort
Secondary outcomes:
measure: Overall Response Rate
timeFrame: At the end of C1 and every 2 cycles thereafter through 6 months following last dose of study drug
measure: Duration of Response
timeFrame: At the end of C1 and every 2 cycles thereafter through 6 months following last dose of study drug
measure: Progression-Free Survival
timeFrame: From Cycle 1 Day 1 (C1D1) until death or study closure, up to 26 months
measure: Overall Survival
timeFrame: From C1D1 until death or study closure, up to 26 months
measure: Pharmacokinetic Profile of E6201 in Plasma: Cmax
timeFrame: Assessed at Cycle 1 Days 1 and 15, Cycle 2 Day 1, pre-dose, 5 minutes following the end of the 2-hour infusion, 2, 4, 8 and 24 hours post-infusion. Summary PK parameters for Cycle 1 Day 1 reported.
measure: Pharmacokinetics of E6201 in Plasma: Tmax
timeFrame: Assessed at Cycle 1 Days 1 and 15, Cycle 2 Day 1, pre-dose, 5 minutes following the end of the 2-hour infusion, 2, 4, 8 and 24 hours post-infusion. Summary PK parameters for Cycle 1 Day 1 reported.
measure: Pharmacokinetic Profile of E6201 in Plasma: AUCT
timeFrame: Assessed at Cycle 1 Days 1 and 15, Cycle 2 Day 1, pre-dose, 5 minutes following the end of the 2-hour infusion, 2, 4, 8 and 24 hours post-infusion. Summary PK parameters for Cycle 1 Day 1 reported.
measure: Pharmacokinetic Profile of E6201 in Plasma: AUCI
timeFrame: Assessed at Cycle 1 Days 1 and 15, Cycle 2 Day 1, pre-dose, 5 minutes following the end of the 2-hour infusion, 2, 4, 8 and 24 hours post-infusion. Summary PK parameters for Cycle 1 Day 1 reported.
measure: Pharmacokinetic Profile of E6201 in Plasma: T1/2
timeFrame: Assessed at Cycle 1 Days 1 and 15, Cycle 2 Day 1, pre-dose, 5 minutes following the end of the 2-hour infusion, 2, 4, 8 and 24 hours post-infusion. Summary PK parameters for Cycle 1 Day 1 reported.
measure: Pharmacokinetic Profile of E6201 in Plasma: CLobs
timeFrame: Assessed at Cycle 1 Days 1 and 15, Cycle 2 Day 1, pre-dose, 5 minutes following the end of the 2-hour infusion, 2, 4, 8 and 24 hours post-infusion. Summary PK parameters for Cycle 1 Day 1 reported.
measure: Pharmacokinetic Profile of E6201 in Plasma: VDobs
timeFrame: Assessed at Cycle 1 Days 1 and 15, Cycle 2 Day 1, pre-dose, 5 minutes following the end of the 2-hour infusion, 2, 4, 8 and 24 hours post-infusion. Summary PK parameters for Cycle 1 Day 1 reported.
measure: Number of Participants With Suppression of pERK at 4 Hours Post-dose
timeFrame: Cycle 1 Day 1, 4 hours post-dose.
measure: Number of Participants With Suppression of pERK at 24 Hours Post-dose
timeFrame: Cycle 1 Day 1, 24 hours post-dose.
measure: Number of Participants With Suppression of pFLT3 at 4 Hours Post-dose
timeFrame: Cycle 1 Day 1, 4 hours post-dose.
measure: Number of Participants With Suppression of pFLT3 at 24 Hours Post-dose
timeFrame: Cycle 1 Day 1, 24 hours post-dose.
measure: Number of Participants With Suppression of pAKT at 4 Hours Post-dose
timeFrame: Cycle 1 Day 1, 4 hours post-dose.
measure: Number of Participants With Suppression of pAKT at 24 Hours Post-dose
timeFrame: Cycle 1 Day 1, 24 hours post-dose.
measure: Number of Participants With Suppression of pERK by PIA at 4 Hours Post-dose
timeFrame: Cycle 1 Day 1, 4 hours post-dose.
measure: Number of Participants With Suppression of in pERK by PIA 24 Hours Post-dose
timeFrame: Cycle 1 Day 1, 24 hours post-dose.
measure: Number of Participants With Suppression of pFLT3 by PIA at 4 Hours Post-dose
timeFrame: Cycle 1 Day 1, 4 hours post-dose.
measure: Number of Participants With Suppression of pFLT3 by PIA at 24 Hours Post-dose
timeFrame: Cycle 1 Day 1, 24 hours post-dose.
Other outcomes:
Locations:
city: Denver
country: United States
facility: Colorado Blood Cancer Institute
state: Colorado
city: Tampa
country: United States
facility: H. Lee Moffitt Cancer Center & research Institute
state: Florida
city: Houston
country: United States
facility: MD Anderson Cancer Center
state: Texas
city: San Antonio
country: United States
facility: Texas Transplant Institute
state: Texas
Study officials:
affiliation: MD Anderson Cancer Center Houston, TX 77030
name: Gautam Borthakur, MD
role: STUDY_CHAIR
References: